Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$161.01 - $317.85 $232,176 - $458,339
-1,442 Reduced 19.13%
6,097 $1.93 Million
Q3 2023

Nov 14, 2023

SELL
$164.66 - $218.08 $317,958 - $421,112
-1,931 Reduced 20.39%
7,539 $1.27 Million
Q2 2023

Aug 11, 2023

SELL
$176.32 - $240.22 $50,251 - $68,462
-285 Reduced 2.92%
9,470 $2.05 Million
Q1 2023

May 12, 2023

BUY
$161.33 - $204.36 $14,035 - $17,779
87 Added 0.9%
9,755 $1.77 Million
Q4 2022

Feb 10, 2023

SELL
$191.53 - $236.82 $416,003 - $514,373
-2,172 Reduced 18.34%
9,668 $1.9 Million
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $930,777 - $2.09 Million
7,519 Added 174.01%
11,840 $2.66 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $106,843 - $162,966
1,137 Added 35.71%
4,321 $547,000
Q1 2022

May 13, 2022

SELL
$98.9 - $132.37 $155,470 - $208,085
-1,572 Reduced 33.05%
3,184 $404,000
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $129,116 - $186,019
1,167 Added 32.52%
4,756 $623,000
Q3 2021

Nov 12, 2021

SELL
$101.2 - $125.87 $6,780 - $8,433
-67 Reduced 1.83%
3,589 $439,000
Q2 2021

Aug 06, 2021

SELL
$107.45 - $135.95 $87,679 - $110,935
-816 Reduced 18.25%
3,656 $417,000
Q1 2021

May 12, 2021

SELL
$95.46 - $133.08 $80,854 - $112,718
-847 Reduced 15.92%
4,472 $538,000
Q4 2020

Feb 08, 2021

SELL
$75.23 - $109.23 $69,963 - $101,583
-930 Reduced 14.88%
5,319 $540,000
Q3 2020

Nov 06, 2020

SELL
$71.31 - $109.74 $303,780 - $467,492
-4,260 Reduced 40.54%
6,249 $483,000
Q2 2020

Aug 17, 2020

BUY
$62.14 - $117.21 $312,502 - $589,449
5,029 Added 91.77%
10,509 $1.17 Million
Q2 2020

Aug 11, 2020

SELL
$62.14 - $117.21 $329,217 - $620,978
-5,298 Reduced 49.16%
5,480 $567,000
Q1 2020

May 14, 2020

BUY
$60.41 - $115.92 $133,445 - $256,067
2,209 Added 25.78%
10,778 $776,000
Q4 2019

Feb 06, 2020

BUY
$11.44 - $123.99 $98,029 - $1.06 Million
8,569 New
8,569 $646,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.